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Abstract
Scleromyxoedema is a rare disease with a progressive and disabling course involving dermal
deposition of mucin and fibroblast proliferation; it is characterized clinically by a diffuse papular
eruption, skin thickening, oedema and decreased skin flexibility, especially of the face and hands.
Current therapy options are based on evidence from a limited number of case reports. The clinical
manifestations and treatment of a 64-year-old man affected by scleromyxoedema with severe skin
involvement of the face, arms and hands, decreased mouth opening and hypomotility of the fingers
are reported. Dysphagia, asthenia and immunoglobulin G lambda monoclonal gammopathy were
also present. Previous treatment with topical and systemic corticosteroids, psoralen plus
ultraviolet A radiation therapy, plasmapheresis, extracorporeal photochemotherapy, hydroxy-
chloroquine and cyclophosphamide had been unsuccessful. Treatment with intravenous immuno-
globulins at a dosage of 2 g/kg monthly was started. Considerable improvements were observed
after seven cycles of therapy, with recovery of skin elasticity, an increase in facial mimic movement,
restoration of joint function and improvement in the modified Rodnan score. There were no
observed side-effects. The patient remains in remission on monthly maintenance intravenous
immunoglobulins, 2 years after initial treatment.
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Introduction
Scleromyxoedema is a rare disease involving
dermal deposition of mucin and ﬁbroblast
proliferation; it is characterized clinically by
a diﬀuse papular eruption, skin thickening,
oedema and decreased skin ﬂexibility, espe-
cially of the face and hands, with a progres-
sive and disabling disease course.1–4 Patients
with scleromyxoedema can also have sys-
temic manifestations.5 Many treatments
have been proposed for scleromyxoedema,
including corticosteroids, retinoids, cyclo-
phosphamide, plasmapheresis, bortezomib,
melphalan, thalidomide, chloroquine, extra-
corporeal photopheresis and photoche-
motherapy such as psoralen plus
ultraviolet A radiation therapy (P-UVA),
cyclosporine and autologous stem-cell trans-
plantation. High doses of intravenous
immunoglobulins have been proposed as a
therapy, based on multiple case reports that
support the eﬃcacy and safety of such
treatment.5–7
Case report
A 64-year-old man presented to the
Department of Dermatology, University-
Hospital of Modena and Reggio Emilia,
Modena, Italy, in November 2012 with
scleromyxoedema, with severe involvement
of the skin of the face, arms and hands,
decreased mouth opening and hypomotility
of the ﬁngers (Figure 1). Dysphagia, asthe-
nia and monoclonal gammopathy of
immunoglobulin G lambda-type were also
present.
The patient had previously been treated
with topical and systemic corticosteroids, P-
UVA therapy, plasmapheresis, extracorporeal
photochemotherapy, hydroxychloroquine
and cyclophosphamide, without any beneﬁt.
Disease severity was assessed using a mod-
iﬁed Rodnan score, which evaluates skin
thickness and papular involvement.8,9 Skin
thickness is rated by clinical palpation using
a 0–3 point scale (0, normal skin; 1, mild
thickness; 2, moderate thickness; 3, severe
thickness with inability to pinch the skin
into a fold) for 17 surface anatomical areas:
face, anterior chest; abdomen; ﬁngers;
forearms; upper arms; thighs; lower legs;
dorsum of hands and feet bilaterally.
Papular involvement is rated according to
the presence of papules (0, no papules; 1,
presence of papules) in each of same 17
anatomical areas. The patient’s total score
was 53 out of a maximum score of 182*.
Treatment with intravenous immunoglobu-
lins at a dosage of 2 g/kg administrated over
5 days once a month was started.
After the ﬁrst infusion cycle, a substantial
improvement was observed. After seven
cycles of therapy, recovery of skin elasticity,
an increase in facial mimic movement and
restoration of joint function was observed
(Figure 2).
The modiﬁed Rodnan score dropped
from 53 to 31. No side-eﬀects were observed.
After 2 years, the patient remains in clinical
remission on maintenance therapy with
intravenous immunoglobulins (2 g/kg once
per month).
The patient gave consent for their case to
be published.
*Minimum score 0 and maximum score 182 (i.e. when
all body sites show the highest score obtained by the
following sum: [18 3]þ [42 3]þ 1þ 1¼ 182. 18 cor-
responds to the total sum of the scores for face, neck,
trunk; 42 corresponds to the total sum of the scores of
upper and lower limbs). Total score is multiplied by the
degree of skin thickening, papules and erythema. The
first ‘‘1’’ indicates presence of itching, second ‘‘1’’
indicates the presence of paresthesiae
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Discussion
Scleromyxoedema is a progressive disease
with a disabling and unpredictable course; in
a few cases it is fatal due to heart or kidney
failure.4,10 The aetiology of scleromyxoe-
dema is still unknown. Therapeutic manage-
ment is based on data from reported cases.
P-UVA therapy, hydroxychloroquine and
cyclophosphamide pulsed therapy were all
unsuccessful in the patient presented here.
A considerable improvement was obtained
with intravenous immunoglobulin 2 g/kg,
administered over 5 days once a month.
The use of intravenous immunoglobulins
as a treatment for scleromyxoedema has
been well documented.5,11,12 The action of
intravenous immunoglobulins is not yet
completely understood, but they seem to
act through an immunomodulatory mech-
anism blocking Fc receptors on splenic
macrophages, inhibiting complement,
modulating cytokines, neutralizing autoan-
tibodies, blocking CD95 and inhibiting
apoptosis.6,13,14 Side-eﬀects are rare and
normally mild.15,16 Some patients require
maintenance intravenous immunoglobulin
Figure 1. (a) Left hand of a patient with scleromyxoedema before treatment, showing oedema, stiffness,
erythema and ulceration. (b) The same hand after 3months’ high-dose intravenous immunoglobulin therapy,
showing resolution of the oedema, erythema and ulceration, good mobility and visible skin folds and wrinkles.
Figure 2. Face of a patient with scleromyxoedema: (a) before treatment, showing severe erythema, papules
and plaques, especially on the glabella, thinning of the eyebrows and reduced mobility; (b) after 3months’
high-dose intravenous immunoglobulin therapy, showing improvement in erythema and oedema and improved
mobility; (c) after 5months’ high-dose intravenous immunoglobulin therapy, showing further improvements in
erythema and mobility, with disappearance of the papules and plaques on the glabella.
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therapy; others need only a few infusions to
obtain permanent remission.5,15
In the patient presented here, the eﬃcacy
of intravenous immunoglobulin therapy was
demonstrated in a reduction in the modiﬁed
Rodnan score. The patient is in clinical
remission 2 years after initial treatment,
with the disappearance of erythema,
oedema and skin stiﬀness and the recovery
of articular motility, facial mimic movement
and improved swallowing.
This case supports the contention that
intravenous immunoglobulins are eﬀective
therapies with a favourable safety proﬁle in
the long-term treatment of scleromyxoe-
dema, especially for patients in whom
other therapeutic options have failed. If the
response is not permanent, maintenance
infusions are required.
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